Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Webinars
and Events

Evolving mCRPC treatment landscape in 2023

Description

The field of prostate cancer treatment is undergoing rapid evolution, with a noticeable shift towards earlier administration of therapies in the treatment pathway. These advancements have resulted in substantial changes in the approach to treating patients with metastatic castration-resistant prostate cancer (mCRPC).

 

In this on-demand webinar, Professor Joe Sullivan provides valuable insights into the positioning of Radium-223 within the treatment pathway and offers recommendations for optimising the sequencing of available treatments. Following Professor Sullivan, Dr. Matt Aldridge offers an overview of how to establish and enhance a Radium-223 service, drawing from his experience at Maidstone and Tunbridge Wells NHS Trust.

 

Interested in learning more? Watch the video below.

 

This webinar was organised and funded by Bayer plc.

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Speakers

Professor Joe Sullivan

Professor Joe Sullivan

Professor Joe O'Sullivan, a distinguished oncologist specialising in prostate cancer, holds the position of Professor of Radiation Oncology at Queen's University Belfast. His fervor lies in the care of prostate cancer patients, and he is deeply motivated to enhance outcomes across all facets of this illness while actively pioneering novel therapeutic approaches, particularly within the domains of External Beam Radiation Therapy and Bone-seeking radionuclide therapy.

Dr. Matt Aldridge

Dr. Matt Aldridge

Dr. Matthew Aldridge holds the esteemed position of Head of Nuclear Medicine Physics at the Maidstone and Tunbridge Wells NHS Trust. At the forefront of healthcare innovation, Dr. Aldridge leads a multidisciplinary team in overseeing the radium-223 service, a critical component of cancer care. With a profound dedication to improving patient outcomes, he continues to drive progress in the dynamic field of nuclear medicine, ensuring the highest standards of care and treatment for those in need.

Radiology run mCRPC treatment clinic: South Midlands Prostate Cancer experience 2022

Radiology run mCRPC treatment clinic: South Midlands Prostate Cancer experience 2022

Be informed of future content relevant to you

Be informed of future content relevant to you

Opt-in to Bayer
communications

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.

OPT-IN TO BAYER COMMUNICATIONS OPT-IN TO BAYER COMMUNICATIONS

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.

 

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.